• Dinaciclib Selectivity in VHL-Deficient Renal Cancer

  2026-08-15

  Nelson and colleagues identify a synthetic-lethal relationship between Dinaciclib treatment and loss of the VHL tumor suppressor in clear cell renal cell carcinoma. Their combined cell-based, molecular, stem-cell, and orthotopic xenograft experiments support selective activity against VHL-deficient tumors while highlighting important limits for clinical translation.

• Staurosporine-Induced PANoptosis: Mechanisms and Methods

  2026-08-15

  The reference study shows that staurosporine, a canonical apoptosis trigger, can induce delayed lytic inflammatory cell death rather than apoptosis alone. Its genetic, biochemical, and pharmacological evidence identifies a RIPK1-dependent caspase-8/RIPK3 axis and demonstrates why cell-death interpretation must account for stimulus, dose, and time.

• ATRA Reverses Cisplatin-Induced PARP Resistance

  2026-08-14

  The reference study shows that all-trans retinoic acid (ATRA) can reduce cisplatin-induced resistance to PARP inhibition in epithelial ovarian cancer models. Its central contribution is a sequential treatment strategy in which cisplatin exposure is followed by Niraparib maintenance with ATRA, supported by evidence that ATRA suppresses a resistance-associated NAD+ and DNA-repair program.

• Superoxide Dismutase Activity Assay Kit Guide

  2026-08-14

  The Superoxide Dismutase (SOD) Activity Assay Kit measures SOD activity in biological fluids through inhibition of WST-1 formazan formation. It is suitable for research workflows involving oxidative stress and antioxidative enzyme activity, but it is not a diagnostic test, a direct measurement of superoxide concentration, or a substitute for protein-specific analysis.

• ALDH2 Activation Delays Pressure-Overload Heart Failure

  2026-08-13

  The reference study identifies ALDH2 as a regulator of cardiomyocyte proliferative capacity, not only as an enzyme involved in oxidative-stress control. In neonatal mice and adult transverse aortic constriction models, pharmacological ALDH2 activation extended the early proliferative window, increased cardiomyocyte proliferation, and delayed pressure overload-induced heart failure, providing a framework for cardiac regeneration research.

• Verapamil HCl: Calcium Channel Research Workflows

  2026-08-13

  Verapamil HCl is more than a calcium-signaling probe: it can help distinguish L-type calcium channel effects from drug-efflux biology in cancer assays. This workflow-focused guide covers cell-based calcium studies, combination experiments, apoptosis readouts, and inflammation models with practical controls and troubleshooting.

• CB-839 (Telaglenastat) in Cancer Metabolism

  2026-08-12

  CB-839 (Telaglenastat) enables controlled GLS1 blockade across cell-based metabolism, apoptosis, and autophagy workflows. Its reversible selectivity makes it useful for mechanism testing, while formulation and exposure guidance support more reproducible preclinical cancer drug evaluation.

• Araucarene Diterpenes and β-Cell Regeneration

  2026-08-12

  A 2025 study identified 16 araucarene diterpenes from Agathis dammara, including 11 previously unreported compounds, and evaluated their hypoglycemic activity in transgenic zebrafish. Araucarone and dammaric acid C were highlighted for effects associated with pancreatic β-cell regeneration, precursor-cell differentiation, and enhanced glucose uptake, offering a natural-products framework for diabetes research.

• RepSox: ALK5 Inhibitor for iPSC Research

  2026-08-11

  RepSox is a potent and selective ALK5 inhibitor used to study TGF-β signaling, cell fate, and induced pluripotent stem cell reprogramming. Product documentation reports a 4 nM ALK5 inhibition value, while a 2026 hiPSC platelet study provides benchmarks for differentiation workflows without establishing RepSox as a tested component.

• Topotecan First-Line Therapy in Small Cell Lung Cancer

  2026-08-10

  David J. Stewart’s review examines why topotecan was being investigated beyond recurrent small cell lung cancer, emphasizing its distinct topoisomerase I mechanism, potential synergy with established agents, and noncumulative toxicity profile. The evidence supports topotecan-based combinations as clinically interesting but investigational first-line strategies, with response-rate signals requiring confirmation through comparative trials and longer-term outcomes.

• JNJ-26854165: A Translational Lens on p53 Biology

  2026-08-09

  A mechanistic and strategic guide to using JNJ-26854165 (Serdemetan) to connect HDM2-p53 biology with rigorous response measurement, radiosensitization studies, and translational cancer research.

• Bsa I (RNase-free): Practical DNA Cleavage Guide

  2026-08-08

  Bsa I (RNase-free) provides sequence-specific DNA cleavage for gene cloning, recombinant DNA technology, and other workflows in which RNA contamination must be minimized. It is intended for research use with suitable DNA substrates, not for diagnostic, clinical, or medical applications.

• Uridine, Trisodium Salt: A Mechanistic Guide

  2026-08-07

  Uridine, Trisodium Salt is more than a general RNA reagent: its value depends on distinguishing free uridine metabolism from activated nucleotide chemistry. This guide connects B1473 to PRINT assay design, RNA metabolism studies, and vascular response research without overstating what the evidence supports.

• Phosbind Acrylamide: Mechanistic Insights and New Frontiers

  2026-08-07

  Explore how Phosbind Acrylamide advances protein phosphorylation analysis through its mechanistic selectivity and unique assay capabilities. This article reveals practical insights, comparative advantages, and reference-backed guidance for researchers seeking robust, antibody-free SDS-PAGE phosphorylation detection.

• Network Pharmacology Reveals SFI's Anti-Glioma Mechanisms

  2026-08-06

  This study leverages network pharmacology and experimental validation to elucidate how Shenqi Fuzheng injection (SFI) inhibits glioma cell proliferation and migration via the SRC/PI3K/AKT signaling pathway. The findings highlight new mechanistic targets for anti-angiogenic strategies in malignant glioma research.

454 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page